Biosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented by Product (Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins), By Technology (Mammalian v/s non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others), By
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationBiosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented by Product (Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins), By Technology (Mammalian v/s non-Mammalian), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others), By
Growing Prevalence of Chronic Disease is Propelling the Market’s Growth
In 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans have type 1 diabetes, including about 244,000 children and adolescents.
Increasing Contract Research Organizations Are Driving the Market’s Growth
Market Segmentation
Market Players
Catalent, Inc., Boehringer Ingelheim GmbH, Alcami Corporation, Inc., Almac Group, Lonza Group AG, Biocon Limited, Avid Bioservice, Inc, Rentschler Biopharma SE, Fujifilm Kyowa Kirin Biologics Co., Ltd., WuXi Biologics, Inc.
Recent Development
For instance, in August 2021, Samsung Biologics announced that it plans to invest USD 205 billion and hire more people to improve its CDMO business in biosimilar, and other things in the coming years. It will benefit several Samsung businesses, including Samsung Bioepis, which deals with biosimilars, and Samsung Biologics, which handles contract manufacturing.
For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments covered | · By Product · By Technology · By Application · By Region |
Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
Country scope | United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
Key companies profiled | Catalent, Inc., Boehringer Ingelheim GmbH, Alcami Corporation, Inc., Almac Group, Lonza Group AG, Biocon Limited, Avid Bioservice, Inc, Rentschler Biopharma SE, Fujifilm Kyowa Kirin Biologics Co., Ltd., WuXi Biologics, Inc. |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy